Official Title DBS-Expert: Automated Deep Brain Stimulation Programming Using Functional Mapping Phase II

Purpose

Deep Brain Stimulation (DBS) surgery is FDA approved for the treatment of Parkinson's Disease. The purpose of this study is to examine a technology (DBS-Expert system) that uses objective measurements to guide DBS programming. The DBS-Expert system analyzes motion data and provides recommendations to the physician or healthcare professional regarding DBS programming settings.

Could this study be right for you?

You may be eligible if you:

• Over the age of 18
• Able and willing to provide informed consent
• Clinical diagnosis of idiopathic Parkinson's Disease
• Implanted Boston Scientific DBS system

Exclusion Criteria

• You are currently participating in any study with an investigational medicinal product (IMP) or investigational device.

Age Range

18 and up

Official Title AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke (ARCADIA)

Purpose

The purpose of this research study is to compare the effects (good and bad) of apixaban with the effects (good and bad) of aspirin in patients with unexplained strokes and atrial cardiopathy to see which is better at prevention of future strokes.

Could this study be right for you?

• You are at least 45 years old
• Clinical diagnosis of ischemic stroke* of unknown cause (ESUS or cryptogenic) in the last 120 days
• Underwent an echocardiogram as part of your stroke work up
• No history of atrial fibrillation (irregular heartbeat)
• No known allergy or intolerance to aspirin or apixaban

*An “ischemic” stroke is an injury to the brain caused by a blocked blood vessel supplying the brain.

Age Range

45 and up

Official Title Movement and Music Intervention for Individuals with Dementia

Purpose

There is some evidence that music based interventions may have a protective effect on the brain in those with dementia. There is also evidence that doing activities that engage the brain through music are beneficial. This study seeks to investigate the potential benefits of a music based intervention for individuals with dementia.

Could this study be right for you?

You may be eligible if you:

• Have a diagnosis of dementia (mild to moderate)
• Are age 60 and older
• Able to follow simple instructions

EXCLUSION CRITERIA:

• Unable to walk 10 feet unassisted
• Presence of bone disorder that impacts walking
• Presence of other neurologic diagnosis that impacts cognitive or motor function such as stroke, Parkinson disease or traumatic brain injury

Age Range

60 and up

Official Title A Phase 2, double-blind, randomized, placebo-controlled cross-over study of nelotanserin versus placebo in Lewy body dementia (LBD) subjects experiencing visual hallucinations (VH)

Purpose

Purpose: To assess the safety of using a drug called nelotanserin with those who have dementia with Lewy body with visual hallucinations.

Could this study be right for you?

• Age: 50-85
• Diagnosis: dementia with Lewy bodies (DLB) or Parkinson's disease dementia (PDD), presence of visual hallucinations that occur more days than not.
• MMSE Score: greater than or equal to 18 (Mini-Mental State Exam--Coordinator will explain)
• Must have a study partner willing to attend visits and ensure compliance with the study

Age Range

50 and up

Official Title A Phase 2, double-blind, randomized, placebo-controlled study of nelotanserin versus placebo in patients with dementia with Lewy bodies (DLB) experiencing REM sleep behaviors (RBD)

Purpose

The purpose of this study is to evaluate the safety of the study drug called nelotanserin and to assess the effects of nelotanserin in those experiencing frequent REM sleep behavior disorders due to dementia with Lewy bodies. Nelotanserin (study drug) is an investigational product, which means that it has not been approved by the U.S. Food and Drug Administration (FDA) or the government health agencies of any other countries.

Could this study be right for you?

• Age: 50-85
• Diagnosis: probable dementia with Lewy bodies or Parkinson's disease dementia
• AND diagnosis of REM sleep behavior disorder (RBD) with frequent RBD episodes
• Must have a study partner willing to serve as a collateral informant for study assessments
• MMSE Score: greater than or equal to 18 (Mini Mental State Examination score to be explained by the coordinator)

Age Range

50 and up

Official Title A Phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB)

Purpose

Purpose of Study:
This research study is being done to test a drug called RVT-101. Our researchers want to assess the effects of RVT-101 versus placebo on function including attention, working memory, reaction time, as well as other measures of cognition in patients with DLB.
RVT-101 is an investigational drug. Investigational means that the drug tested in this study has not been approved by the U.S. Food and Drug Administration (FDA) or any other Health Authority including European or Canadian Health Authorities.

Could this study be right for you?

• Ages 50-85
• Diagnosis of Probable dementia with Lewy bodies
• Must have a study partner willing to attend visits and ensure compliance with the study
• Score on MMSE of 14-26 (Mini–Mental State Examination--the study coordinator can explain this)

Age Range

50 and up

Official Title Electrographic and Neurohormonal Characteristics of Adolescent Nausea during Tilt Table Testing, The ENCHANT Study

Purpose

Researchers are looking for healthy young volunteers in order to understand what happens when someone faints. They want to know about changes in children and teenagers who frequently faint, and compare those who faint to healthy people who do not normally faint.

Researchers want to learn more about what happens to the brain and the stomach when people faint. The electroencephalogram or EEG measures brainwaves. The electrogastrogram or EGG records stomach electrical activity. The goal of this study is to measure how gastric electricity changes during fainting. They will use the EEG to confirm that fainting happened. Researchers will compare results of those who are healthy to patients who faint.

Some individuals with fainting or frequent lightheadedness can have excessive nausea. This is'orthostatic nausea', which means nausea with standing. The purpose of this study is to measure hormones from the blood and electrical changes in the stomach during tilt-table testing in patients and healthy controls. Researchers hope to identify the physiologic changes that lead to orthostatic nausea.

Could this study be right for you?

• Ages 12-20
• No prior fainting or frequent dizziness/lightheadedness
• No prior anxiety or depression
• No medicines that can affect dizziness/lightheadedness
• No difficulties with nausea or abdominal pain
• Normal weight

Age Range

12 and up

Official Title A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease Alternate Official Title: 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)

Purpose

The EMERGE study will assess the safety and potential effectiveness of an investigational medication to determine whether it can slow the progression of symptoms in early Alzheimer's Disease, such as memory loss.

Find on CT.gov- https://clinicaltrials.gov/ct2/show/study/NCT02484547?term=EMERGE&rank=…

Could this study be right for you?

In order to qualify you must:

• Be between 50-85 years of age
• Be experiencing symptoms that might be related to early Alzheimer's disease, such as problem with memory or thinking clearly

Additional eligibility criteria will be explained by study staff contact.

Age Range

50 and up

Official Title A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis.

Purpose

This study is being done to determine how effective an investigational new drug (Ublituximab) is when given to those who have multiple sclerosis and what side effects may happen. Ublituximab has not yet been approved by the United States Food and Drug Administration (FDA), and is for use in clinical trials for people with relapsing forms of multiple sclerosis. The purpose of this clinical trial is to determine what dose and effect the study drug, Ublituximab, has on Multiple Sclerosis (MS) and those who have MS.

Could this study be right for you?

• Ages 18-55
• Diagnosis of Relapsing Multiple Sclerosis
• 2 or more relapses in prior 2 years or 1 relapse in the year prior to screening
• Active disease
• Other eligibility criteria to be discussed during screening

Age Range

18 and up

Official Title AN OPEN-LABEL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO HAVE HAD A SUBOPTIMAL RESPONSE TO AN ADEQUATE COURSE OF DISEASE-MODIFYING TREATMENT

Purpose

The purpose of this study is to determine the effectiveness of the drug ocrelizumab in those with Remitting Relapsing Multiple Sclerosis who have not had good outcomes with other Disease-Modifying Treatment.

Could this study be right for you?

You may be eligible for this study if you:

• are between the ages of 18 and 55 years
• have a definite diagnosis of Relapsing Remitting MS
• have a length of disease duration (from first symptom) of less than or equal to 8 years
• have been treated with no more than 2 prior disease-modifying treatments (discontinued due to lack of efficiency)

Age Range

18 and up